Lactobacillus rhamnosus GG – sprzymierzeniec w walce z antybiotykoopornością?

Lactobacillus rhamnosus GG – an ally in the fight against antibiotic resistance?

Bożena Cukrowska

Pracownia Immunologii Zakładu Patologii, Instytut „Pomnik – Centrum Zdrowia Dziecka” w Warszawie

Bożena Cukrowska
Kierownik Pracowni Immunologii
Zakład Patologii
Instytut – Pomnik Centrum Zdrowia Dziecka
Al. Dzieci Polskich 20, 04-730 Warszawa
Tel.: 22 815 19 69

Wpłynęło: 08.08.2018
Zaakceptowano: 07.09.2018
Opublikowano on-line: 20.09.2018

Cytowanie

Cukrowska B. Lactobacillus rhamnosus GG – sprzymierzeniec w walce z antybiotykoopornością? Zakażenia XXI wieku 2018;1(4):169–174. doi: 10.31350/zakazenia/2018/4/Z2018029

WERSJA ELEKTRONICZNA

Streszczenie:
Antybiotykooporność mikroorganizmów stanowi obecnie jeden z najpoważniejszych problemów medycyny. Strategia walki z antybiotykoopornością obejmuje wiele obszarów, wśród których ogromne znaczenie ma odpowiedzialne stosowanie antybiotyków oraz poszukiwanie nowych substancji o działaniu przeciwbakteryjnym. Probiotyki, definiowane jako żywe mikroorganizmy, korzystnie wpływające na zdrowie, mogą być pomocne w zwalczaniu antybiotykooporności. Modulują skład mikrobioty jelitowej, eliminują oporne patogeny z organizmu oraz wzmacniają odporność, co skutkuje obniżeniem ryzyka zakażeń i zmniejszeniem antybiotykoterapii. Lactobacillus rhamnosus GG (LGG) to szczep probiotyczny o najbardziej udowodnionych efektach klinicznych w obszarze walki z antybiotykoopornością. Doustne podawanie LGG obniża zarówno ryzyko infekcji, w tym infekcji szpitalnych, jak też stosowanie antybiotyków u małych dzieci oraz zmniejsza nosicielstwo enterokoków wankomycynoopornych u dzieci i dorosłych.

Słowa kluczowe: antybiotykooporność, probiotyki, Lactobacillus rhamnosus GG

Abstract:
Antibiotic resistance of microorganisms is currently one of the most serious problems of medicine. The strategy of combating antibiotic resistance covers many areas, among which the responsible use of antibiotics and the search for new substances with antimicrobial activity is of great importance. Probiotics, defined as live microorganisms beneficial to health, can be helpful in combating antibiotic resistance. Probiotics modulate the composition of intestinal microbiota, eliminate resistant pathogens from the body and strengthen immunity, which results in lowering the risk of infections and reducing antibiotic therapy. Lactobacillus rhamnosus GG (LGG) is a probiotic strain with the most proven clinical effects in the fight against antibiotic resistance. Oral administration of LGG reduces the risk of infection, including nosocomial infections and the use of antibiotics in young children, and reduces the incidence of vancomycin-resistant enterococci in children and adults.

Key words: antibiotic resistance, probiotics, Lactobacillus rhamnosus GG

  1. Raport WHO, Antimicrobial resistance: global report on surveillance, 2014.
  2. Wang Y, Li X, Ge T i wsp. Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95(31):e4509 [doi: 10.1097/MD.0000000000004509].
  3. Korpela K, Salonen A, Virta LJ i wsp. Lactobacillus rhamnosus GG Intake Modifies Preschool Children’s Intestinal Microbiota, Alleviates Penicillin-Associated Changes, and Reduces Antibiotic Use. PLoS One 2016;25,11(4):e0154012 [doi: 10.1371/journal.pone.0154012].
  4. Hojsak I, Szajewska H, Canani RB i wsp. Probiotics for the prevention of nosocomial diarrhea in children. J Pediatr Gastroenterol Nutr 2018;66(1):3–9 [doi: 10.1097/MPG.0000000000001637].
  5. Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011;45(10):872–877 [doi: 10.1097/MCG.0b013e318227439f].
  6. Manley KJ, Fraenkel MB, Mayall BC i wsp. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust 2007;186(9):454–457.
  7. Mazur E, Klag S. Mechanizmy lekooporności bakterii. Medycyna Rodzinna. 2004;6:278–281 .
  8. Neonakis IK, Samonis G, Messaritakis H. Resistance status and evolution trends of Klebsiella pneumoniae isolates in a university hospital in Greece: ineffectiveness of carbapenems and increasing resistance to co listin. Chemotherapy 2010;56:448–452 [doi: 10.1159/000320943].
  9. David M, Daum S. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010;23(3):616–687 [doi: 10.1128/CMR.00081-09].
  10. Buffie ChG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013;13(11):790–801 [doi: 10.1038/nri3535].
  11. Tavadze M, Rybicki L, Mossad S i wsp. Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2014;49(10):1310–1316 [doi: 10.1038/bmt.2014.150].
  12. Mitsou EK, Kirtzalidou E, Pramateftaki P, Kyriacou A. Antibiotic resistance in faecal microbiota of Greek healthy infants. Benef Microbes 2010;1(3):297–306 [doi: 10.3920/BM2010.0007].
  13. FAO/WHO Consultations and Workshops. Safety assessment of foods derived from genetically modified microorganisms. Report of a Joint FAO/WHO Expert Consultation on Foods Derived from Biotechnology 2001:11–29.
  14. Cukrowska B, Czarnowska E. Wpływ probiotyków na układ immunologiczny. Zakażenia 2007;1:59–64.
  15. Spinler JK, Taweechotipatr M, Rognerud CL i wsp.: Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activites targeting diverse enteric bacterial pathogens. Anaerobe. 2008;14(3):166–171 [doi: 10.1016/j.anaerobe.2008.02.001].
  16. Marianelli C, Cifani N, Pasquali P. Evaluation of antimicrobial activity of probiotic bacteria against Salmonella enterica subsp. enterica serovar typhimurium 1344 in a common medium under different environmental conditions. Res Microbiol 2010;161(8):673–680 [doi: 10.1016/j.resmic.2010.06.007].
  17. Johnson-Henry KC, Hagen KE, Gordonpour M i wsp. Surface-layer protein extracts from Lactobacillus helveticus inhibit enterohaemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells. Cell Microbiol. 2007;9(2):356–367 [doi: 10.1111/j.1462-5822.2006.00791.x].
  18. Tytgat HL, Douillard FP, Reunanen J i wsp. Lactobacillus rhamnosus GG Outcompetes Enterococcus faecium via Mucus-Binding Pili: Evidence for a Novel and Heterospecific Probiotic Mechanism. Appl Environ Microbiol 2016;82(19):5756–5762 [doi: 10.1128/AEM.01243-16].
  19. Petrova MI, Imholz NC, Verhoeven TL i wsp. Lectin-Like Molecules of Lactobacillus rhamnosus GG Inhibit Pathogenic Escherichia coli and Salmonella Biofilm Formation. PLoS One 2016;11(8):e0161337 [doi: 10.1371/journal.pone.0161337].
  20. Kozakova H, Schwarzer M, Tuckova L i wsp. Colonization of germ-free mice with a mixture of three Lactobacillus strains enhances the integrity of gut mucosa and ameliorates allergic sensitization. Cell Mol Immunol 2016;13(2):251–262 [doi: 10.1038/cmi.2015.09].
  21. Khailova L, Baird CH, Rush AA i wsp. Lactobacillus rhamnosus GG improves outcome in experimental pseudomonas aeruginosa pneumonia: potential role of regulatory T cells. Shock. 2013;40(6):496–503 [doi: 10.1097/SHK.0000000000000066].
  22. Khailova L, Baird CH, Rush AA i wsp. Lactobacillus rhamnosus GG treatment improves intestinal permeability and modulates inflammatory response and homeostasis of spleen and colon in experimental model of Pseudomonas aeruginosa pneumonia. Clin Nutr. 2017;36(6):1549–1557 [doi: 10.1016/j.clnu.2016.09.025].
  23. Silverstein M, Sales AE, Koepsell TD. Health care utilization and expenditures associated with child care attendance: a nationally representative sample. Pediatrics 2003;111:e371–375.
  24. Hojsak I. Probiotics in children: What is the evidence? Pediatr Gastroenterol Hepatol Nutr 2017;20(3):139–146 [doi: 10.5223/pghn.2017.20.3.139].
  25. World Health Organization. Report on the burden of endemic health care-associated infection worldwide. Geneva, 2011.
  26. Szajewska H, Canani RB, Guarino A i wsp. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr 2016;62(3):495–506 [doi: 10.1097/MPG.0000000000001081].
  27. de Andrade Calaça PR, Bezerra RP, Albuquerque WWC i wsp. Probiotics as a preventive strategy for surgical infection in colorectal cancer patients: a systematic review and meta-analysis of randomized trials. Transl Gastroenterol Hepatol 2017;2:67 [doi: 10.21037/tgh.2017.08.01.
  28. Vidal M, Forestier C, Charbonnel N i wsp. Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. J Clin Microbiol 2010;48:2595–2598 [doi: 10.1128/JCM.00473-10].
  29. de Regt MJ, Willems RJ, Hené RJ i wsp. Effects of probiotics on acquisition and spread of multiresistant enterococci. Antimicrob Agents Chemother 2010;54(7):2801–2805 [doi: 10.1128/AAC.01765-09].
  30. Tannock GW, Tiong IS, Priest P i wsp. Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities. J Med Microbiol 2011;60:366–370 [doi: 10.1099/jmm.0.025874-0].
  31. Mohan R, Koebnick C, Schildt J i wsp.: Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. J Clin Microbiol. 2006;44(11):4025–4031 [doi: 10.1128/JCM.00767-06].
  32. Sullivan A, Johansson A, Svenungsson B, Nord CE. Effect of Lactobacillus F19 on the emergence of antibiotic-resistant microorganisms in the intestinal microflora. J Antimicrob Chemother 2004;54(4):791–797 [doi: 10.1093/jac/dkh406].
  33. Salomão MC, Heluany-Filho MA, Menegueti MG i wsp. A randomized clinical trial on the effectiveness of a symbiotic product to decolonize patients harboring multidrug-resistant Gram-negative bacilli. Rev Soc Bras Med Trop 2016;49(5):559–566 [doi: 10.1590/0037-8682-0233-2016].
  34. Warrack S, Panjikar P, Duster M, Safdar N. Tolerability of a probiotic in subjects with a history of methicillin-resistant Staphylococcus aureus colonisation. Benef Microbes 2014;5(4):389–395 [doi: 10.3920/BM2013.0062].

Nie zgłoszono.

MAVIPURO Polska Sp. z o.o.
ul. Wyspowa 2/13
03-687 Warszawa
Tel.: +48 22 110 03 81
Fax:   +48 22 378 28 51
e-mail: kontakt@mavipuro.pl

Regulamin
Polityka prywatności